Patents by Inventor Yong-Seop PARK

Yong-Seop PARK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Buffer unit and method for storaging substrate type sensor for measuring of horizontality of a substrate support member provided on a temperature varying atmosphere
    Patent number: 11933808
    Abstract: A buffer unit for temporarily storing a substrate includes a housing having a space for storing a substrate therein, one or more slots disposed within the housing for placing a substrate thereon, and a holding unit disposed at a bottom portion of the housing, having a flat and non-inclined top surface, and comprising a built-in wireless charging module. A substrate type sensor is stored at the holding unit.
    Type: Grant
    Filed: December 29, 2021
    Date of Patent: March 19, 2024
    Assignee: SEMES CO., LTD.
    Inventors: Young Seop Choi, Yong-Jun Seo, Sang Hyun Son, Ji Young Lee, Gyeong Ryul Kim, Sun Yong Park
  • REFINING METHOD OF OPHTHALMIC PROTEIN PHARMACEUTICAL
    Publication number: 20220267411
    Abstract: The present invention relates to a method for refining an ophthalmic protein pharmaceutical with an isoelectric point in a particular range by applying cation exchange chromatography or anion exchange chromatography. According to the present invention, high-purity ophthalmic protein pharmaceutical can be produced more economically by applying three or four chromatography processes.
    Type: Application
    Filed: September 9, 2019
    Publication date: August 25, 2022
    Inventors: Byung-Jhip Ha, Yong-Seop Park, Mee-Ran Seo, Jae-Ho Lee, Dong-Kyu Kim, Jae-In Jeong
  • Aflibercept ophthalmic pharmaceutical composition
    Patent number: 10646546
    Abstract: Provided is an ophthalmic pharmaceutical composition having a certain pH, comprising aflibercept as an active ingredient and an acetate salt buffering agent, wherein the composition is free of an ionic tonicity agent, remarkably reduces the formation of dimeric and multimeric impurities, and maintains the biological activity in a high level for a long time, under the accelerated and stress conditions as well as under the cold storage condition.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: May 12, 2020
    Assignee: SAM CHUN DANG PHARM. CO., LTD.
    Inventors: Guang-Jin Im, Byung-Jhip Ha, Na-Won Park, Yong-Seop Park
  • OPHTHALMIC PHARMACEUTICAL COMPOSITION
    Publication number: 20190160145
    Abstract: Provided is an ophthalmic pharmaceutical composition having a certain pH, comprising aflibercept as an active ingredient and an acetate salt buffering agent, wherein the composition is free of an ionic tonicity agent, remarkably reduces the formation of dimeric and multimeric impurities, and maintains the biological activity in a high level for a long time, under the accelerated and stress conditions as well as under the cold storage condition.
    Type: Application
    Filed: October 13, 2017
    Publication date: May 30, 2019
    Applicant: SAM CHUN DANG PHARM. CO., LTD.
    Inventors: Guang-Jin IM, Byung-Jhip HA, Na-Won PARK, Yong-Seop PARK